RE: Praluent (Alirocumab)-Induced Renal Injury

J Pharm Pract. 2018 Apr;31(2):138-139. doi: 10.1177/0897190017734429. Epub 2017 Oct 3.

Authors

Robert S Rosenson¹, Dominique Larrey², David D Waters³, Anders G Olsson⁴; Members of the Phase 3 Data Monitoring Committee for PRALUENT

Affiliations

¹ 1 Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² 2 Hepato-Gastroentérologie, CHU de Montpellier, Hôpital Saint-Eloi, Montpellier, France.
³ 3 Division of Cardiology, San Francisco General Hospital, San Francisco, CA, USA.
⁴ 4 Faculty of Health Sciences, Linköping University and Heart Center, Stockholm, Sweden.

No abstract available

Keywords: acute renal injury; alirocumab; rosuvastatin.

Publication types

Comment

MeSH terms

Antibodies, Monoclonal*
Antibodies, Monoclonal, Humanized
Cholesterol, LDL
Humans
Kidney*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cholesterol, LDL
alirocumab